Literature DB >> 17700544

Stable gene transfer to muscle using non-integrating lentiviral vectors.

Luis Apolonia1, Simon N Waddington, Carolina Fernandes, Natalie J Ward, Gerben Bouma, Michael P Blundell, Adrian J Thrasher, Mary K Collins, Nicola J Philpott.   

Abstract

Human immunodeficiency virus (HIV)-based lentiviral vectors (LVs) hold immense promise for gene delivery applications because of their relatively large packaging capacity and their ability to infect a range of cell types. The genome of HIV non-specifically integrates into the host genome, and this promotes efficient, stable transgene expression in dividing cells. However, integration can also be problematic because of variations in gene expression among cells, possible gene silencing and, most importantly, insertional mutagenesis which can lead to undesirable effects such as malignant transformation. In order to alleviate these problems, we have developed a range of non-integrating LVs (NILVs) by introducing point mutations into the catalytic site, chromosome binding site, and viral DNA binding site of the viral integrase (IN). In addition, we have mutated the IN attachment (att) sites within the HIV long terminal repeats (LTRs). All of the vectors produced show efficient reverse transcription and transgene expression in dividing cells and prolonged expression in non-dividing myotubes. Finally, we show that NILV can be used for achieving highly effective gene transfer and expression in muscle in vivo.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17700544     DOI: 10.1038/sj.mt.6300281

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  87 in total

Review 1.  Hybrid lentiviral vectors.

Authors:  Waseem Qasim; Conrad A Vink; Adrian J Thrasher
Journal:  Mol Ther       Date:  2010-04-20       Impact factor: 11.454

2.  Nonintegrating foamy virus vectors.

Authors:  David R Deyle; Yi Li; Erik M Olson; David W Russell
Journal:  J Virol       Date:  2010-06-30       Impact factor: 5.103

Review 3.  Immunization delivered by lentiviral vectors for cancer and infectious diseases.

Authors:  Biliang Hu; April Tai; Pin Wang
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

4.  Notable reduction in illegitimate integration mediated by a PPT-deleted, nonintegrating lentiviral vector.

Authors:  Boris Kantor; Matthew Bayer; Hong Ma; Jude Samulski; Chengwen Li; Thomas McCown; Tal Kafri
Journal:  Mol Ther       Date:  2010-12-14       Impact factor: 11.454

5.  Respiratory syncytial virus engineered to express the cystic fibrosis transmembrane conductance regulator corrects the bioelectric phenotype of human cystic fibrosis airway epithelium in vitro.

Authors:  Anna R Kwilas; Mark A Yednak; Liqun Zhang; Rachael Liesman; Peter L Collins; Raymond J Pickles; Mark E Peeples
Journal:  J Virol       Date:  2010-05-26       Impact factor: 5.103

Review 6.  Viral vectors for gene delivery to the central nervous system.

Authors:  Thomas B Lentz; Steven J Gray; R Jude Samulski
Journal:  Neurobiol Dis       Date:  2011-10-07       Impact factor: 5.996

Review 7.  Integration-deficient lentiviral vectors: a slow coming of age.

Authors:  Klaus Wanisch; Rafael J Yáñez-Muñoz
Journal:  Mol Ther       Date:  2009-06-02       Impact factor: 11.454

8.  Sleeping beauty transposition from nonintegrating lentivirus.

Authors:  Conrad A Vink; H Bobby Gaspar; Richard Gabriel; Manfred Schmidt; R Scott McIvor; Adrian J Thrasher; Waseem Qasim
Journal:  Mol Ther       Date:  2009-05-05       Impact factor: 11.454

9.  Nonintegrating lentivector vaccines stimulate prolonged T-cell and antibody responses and are effective in tumor therapy.

Authors:  Katarzyna Karwacz; Sayandip Mukherjee; Luis Apolonia; Michael P Blundell; Gerben Bouma; David Escors; Mary K Collins; Adrian J Thrasher
Journal:  J Virol       Date:  2009-01-28       Impact factor: 5.103

10.  PRAS40 plays a pivotal role in protecting against stroke by linking the Akt and mTOR pathways.

Authors:  Xiaoxing Xiong; Rong Xie; Hongfei Zhang; Lijuan Gu; Weiying Xie; Michelle Cheng; Zhihong Jian; Kristina Kovacina; Heng Zhao
Journal:  Neurobiol Dis       Date:  2014-02-27       Impact factor: 5.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.